

General Announcement::Trendlines Receives Additional Purchase Order from US-based Medical Device Public Company

Issuer & Securities

Issuer/ Manager	THE TRENDLINES GROUP LTD.
Securities	THE TRENDLINES GROUP LTD. - IL0011328858 - 42T
Stapled Security	No

Announcement Details

Announcement Title	General Announcement
Date & Time of Broadcast	01-Mar-2016 07:03:38
Status	New
Announcement Sub Title	Trendlines Receives Additional Purchase Order from US-based Medical Device Public Company
Announcement Reference	SG160301OTHR51QI
Submitted By (Co./ Ind. Name)	Yosef Ron
Designation	Joint Company Secretary
Description (Please provide a detailed description of the event in the box below)	Please see attached.
Attachments	Trendlines Labs - US P.O. Feb 2016 01 03 2016.pdf Total size =79K

Like



THE TRENDLINES GROUP LTD.

(Incorporated in Israel)

(Company Registration No. 513970947)

The Trendlines Group Ltd. Receives Additional Purchase Order from US-based Medical Device Public Company

The board of directors (the “**Board**”) of The Trendlines Group Ltd. (the “**Company**” or “**The Trendlines Group**” and, together with its subsidiaries and associated companies, the “**Group**”) wishes to announce that the Company received an additional purchase order (“**PO**”) from a large US medical device company (“**MDC**”). Under the PO, the Company’s “Trendlines Labs” unit will endeavour to develop an innovative medical device for manufacture and marketing by the MDC.

Background

Trendlines Labs, the in-house innovation centre of The Trendlines Group, creates and develops technologies and products to meet critical unmet market needs. Trendlines Labs’ multidisciplinary team of scientists, engineers, and medical professionals brings extensive project management experience to its focused and efficient approach to innovation.

Matching The Trendlines Group’s innovation and product development expertise with the MDC’s depth of manufacturing experience and market reach, the PO could serve to expand and enhance the extensive product portfolio of this market-leading MDC. This PO was received following the completion and market introduction of a completed product as a result of successful multi-year cooperation efforts between the Company and the MDC. The MDC is a US-based public company with worldwide annual sales exceeding US\$ 5 billion.

Principal Terms of the PO

Under the PO, Trendlines Labs will engage in certain development work with the MDC in exchange for payments during the course of 2016 and potential additional future consideration. The Trendlines Group and the MDC have further agreed to negotiate a framework agreement that would define the commercial relationship between the parties.

Financial Impact

The PO is not expected to have any material impact on the Group’s earnings per share and net tangible assets per share for the financial year ending 31 December 2016.

Interest of Directors and Substantial Shareholders

None of the Company’s directors, substantial shareholders and any of their respective associates have any interest, direct or indirect (other than through their shareholdings in the Company), in the above transaction.

**BY ORDER OF THE BOARD
THE TRENDLINES GROUP LTD**

Yossi Ron,
Joint Company Secretary

1 March 2016

The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.